Dr. Alice Mims
Claim this profileOhio State University Comprehensive Cancer Center
Expert in Acute Myelogenous Leukemia
Expert in Acute Myeloid Leukemia
19 reported clinical trials
42 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
Global LeaderHLA-A positive
FLT3 positive
TP53 positive
2Acute Myeloid Leukemia
Global LeaderFLT3 positive
TP53 positive
IDH positive
Affiliated Hospitals
Clinical Trials Alice Mims is currently running
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
SNDX-5613 + Chemotherapy
for Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.
Recruiting1 award Phase 1
More about Alice Mims
Clinical Trial Related6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Alice Mims has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Daunorubicin
- Ivosidenib
- SNDX-5613
Breakdown of trials Alice Mims has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alice Mims specialize in?
Alice Mims focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved HLA-A positive patients, or patients who are FLT3 positive.
Is Alice Mims currently recruiting for clinical trials?
Yes, Alice Mims is currently recruiting for 9 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Alice Mims has studied deeply?
Yes, Alice Mims has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Alice Mims?
Apply for one of the trials that Alice Mims is conducting.
What is the office address of Alice Mims?
The office of Alice Mims is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.